Novartis Pharma (encorafenib (LGX818)) Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
Asset Purch.
- Financing Rounds
-
1
Novartis Pharma (encorafenib (LGX818)) General Information
Description
A key protein kinase in the RAS/RAF/MEK/ERK signaling pathway. It regulates several key cellular activities including proliferation, differentiation, migration, survival and angiogenesis.
Contact Information
Corporate Office
- Boulder, CO
- United States
Corporate Office
- Boulder, CO
- United States
Novartis Pharma (encorafenib (LGX818)) Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Novartis Pharma (encorafenib (LGX818)) Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Novartis Pharma (encorafenib (LGX818)) FAQs
-
Where is Novartis Pharma (encorafenib (LGX818)) headquartered?
Novartis Pharma (encorafenib (LGX818)) is headquartered in Boulder, CO.
-
What industry is Novartis Pharma (encorafenib (LGX818)) in?
Novartis Pharma (encorafenib (LGX818))’s primary industry is Buildings and Property.
-
Is Novartis Pharma (encorafenib (LGX818)) a private or public company?
Novartis Pharma (encorafenib (LGX818)) is a Private company.
-
What is Novartis Pharma (encorafenib (LGX818))’s current revenue?
The current revenue for Novartis Pharma (encorafenib (LGX818)) is
. -
Who are Novartis Pharma (encorafenib (LGX818))’s investors?
Novartis has invested in Novartis Pharma (encorafenib (LGX818)).
-
When was Novartis Pharma (encorafenib (LGX818)) acquired?
Novartis Pharma (encorafenib (LGX818)) was acquired on 02-Mar-2015.
-
Who acquired Novartis Pharma (encorafenib (LGX818))?
Novartis Pharma (encorafenib (LGX818)) was acquired by Array BioPharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »